All News
Filter News
Found 796,712 articles
-
Genascence Announces Initiation of Phase 1b Clinical Trial of GNSC-001 Gene Therapy for Knee Osteoarthritis (OA)
1/3/2024
Genascence Corporation today announced the initiation of its Phase 1b clinical trial of GNSC-001 for the treatment of knee osteoarthritis (OA) (DONATELLO).
-
ENYO Pharma Announces a €39 Million Series C Financing and FDA Clearance to Advance Vonafexor in a Phase 2 Clinical Trial for Patients With Alport Syndrome
1/3/2024
ENYO Pharma (“ENYO”) announced that it has received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 clinical study of Vonafexor, a highly selective FXR agonist, for the treatment of Alport Syndrome.
-
Ampersand Biomedicines Acquires AbCheck to Accelerate Platform and Product Development
1/3/2024
Acquisition amplifies Ampersand’s in-house capabilities to generate AND-Body™ Therapeutics - programmed biologics across a broad range of diseases
-
Bench International Enters into Ground Breaking Strategic Alliance with Ashton Tweed
1/3/2024
First of its Kind Alliance Extends Mutual Service Offerings to Better Serve Clients
-
Ultragenyx Announces Completion of Enrollment in Global Phase 1/2 Trial of GTX-102 in Pediatric Patients with Angelman Syndrome
1/3/2024
Ultragenyx Pharmaceutical Inc. today announced the completion of patient enrollment in its Phase 1/2 clinical trial of GTX-102 for the treatment of pediatric patients with Angelman syndrome (AS).
-
VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors
1/3/2024
VYNE Therapeutics Inc. today announced the appointment of Christine Borowski, Ph.D., to its board of directors, effective as of January 1, 2024.
-
Fluzone High-Dose Quadrivalent vaccine remains preferentially recommended to protect adults 65 years of age and older against influenza
1/3/2024
The National Advisory Committee on Immunization's (NACI) annual Statement on Seasonal Influenza Vaccine for 2024-2025 continues to recommend Fluzone® High-Dose Quadrivalent (Influenza Vaccine) among the preferential influenza vaccines to protect adults 65 years of age and older against influenza.
-
Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
1/3/2024
Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced completion of enrollment in the Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer’s disease.
-
BridgeBio announces FDA clearance of IND application for BBO-8520, a first-in-class direct inhibitor of KRASG12C (ON)
1/3/2024
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, has announced that the United States Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for BBO-8520, a first-in-class orally bioavailable and highly potent small molecule direct inhibitor of KRASG12C (ON) state.
-
BridGene Biosciences Announces Strategic Collaboration with Galapagos to Discover Small Molecule Drugs for Oncology Targets
1/3/2024
BridGene Biosciences, Inc., a leader in the discovery of small molecule drugs for traditional "hard-to-drug" targets, announced today a strategic collaboration and licensing agreement with Galapagos NV (Euronext & NASDAQ: GLPG).
-
MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline
1/3/2024
MaxCyte, Inc. today announced the signing of a strategic platform license (SPL).
-
Arch Biopartners Receives Approval from the Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
1/3/2024
Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it has received approval in Turkey from the Ministry of Health to proceed with a Phase II trial for LSALT peptide, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).
-
New Study Reports IceCure's ProSense® Boosts Immune Response Against Cancer: Enhances CD8+ T Cell Response
1/3/2024
IceCure Medical Ltd. (Nasdaq: ICCM), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the publication of a study titled "Piezo1 facilitates optimal T cell activation during tumor challenge" in the highly influential peer-reviewed journal OncoImmunology.
-
Kyverna's KYV-101 Receives U.S. FDA Clearance for Treatment of Patients With Refractory, Progressive Multiple Sclerosis in the KYSA-7 Phase 2 Trial
1/3/2024
Kyverna Therapeutics, Inc. (Kyverna) today announced the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for its autologous, fully human CD19 chimeric antigen receptor (CAR) T-cell product candidate, KYV-101, to be used for the treatment of multiple sclerosis (MS).
-
New Published Data Demonstrates Correlation Between Itch Cytokine Interleukin-31 Reduction and Pruritis Improvement in Primary Biliary Cholangitis in Phase 3 Post-Hoc Analysis of CymaBay's Seladelpar
1/3/2024
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced the first published findings demonstrating the impact of seladelpar on serum interleukin-31 (IL-31) levels and its correlation with pruritus improvement in people with primary biliary cholangitis (PBC).
-
ChemDiv Marks a Milestone as Orionis Biosciences' Novel Immunotherapy Enters Phase I Clinical Trials
1/3/2024
ChemDiv Inc, a leading provider of drug discovery platforms and development solutions, celebrates a significant milestone in collaboration with Orionis Biosciences: the commencement of Phase I clinical trials for ORB-011, a cutting-edge attenuated, cis-targeted interferon immunotherapy compound.
-
K2 Medical Research Join Forces with Magruder Eye Institute to Advance Alzheimer's Clinical Trial Accessibility Through RetiSpec's AI-Driven Eye Test
1/3/2024
K2 Medical Research, a privately-owned clinical research facility in the greater Orlando area, has teamed up with Magruder Eye Institute and RetiSpec in a research pilot to enhance access to clinical trials.
-
Medytox, Inc. Announces the Formation of Luvantas Subsidiary and Appointment of Key Executives
1/3/2024
Medytox, Inc. is pleased to announce the formation of Luvantas, Inc. as its wholly-owned North American subsidiary.
-
Wugen Strengthens Executive Leadership Team with Appointment of Keith Vendola, M.D., M.B.A. as Chief Financial OfficerDr. Vendola Brings Deep, Hands-On Industry Strategy, Operational and Financial Expertise to the Role
1/3/2024
Wugen, Inc. announced the appointment of Keith Vendola, M.D., M.B.A., as chief financial officer, effective October 2023.
-
Curtis A. Cluff Named Chief Executive Officer of BioPhotas, Inc.
1/3/2024
BioPhotas, Inc., the market leader in therapeutic LED Light Therapy devices announced that its Board of Directors has named Curtis A. Cluff as the Company's CEO.